DV
Dividend Vision

ACIU — AC Immune Ltd

AC Immune Ltd (ACIU)

Total return is -84.1% over the past 9.9 years, 404.0 points behind SPY at 319.9%. Its deepest 1-year drawdown was 46.9%.

AC Immune Ltd is a single-stock equity holding that tracks the performance of a Swiss biopharmaceutical company focused on neurodegenerative disease research and development. The fund does not maintain a dividend distribution profile, making it unsuitable for income-focused investors seeking regular dividend payments. This equity holding appeals primarily to growth-oriented investors interested in exposure to the biotechnology sector and the company's pipeline of therapeutic candidates.

ACIU key facts

Asset type
Stock
Asset class
Equity
Inception date
09/23/2016
Last close
$2.49
Market cap
$223,901,872
Average volume
133235.0
Beta
1.569
Payout ratio
0.0
Forward P/E
11.236
EPS
$-0.82